Hyaluronan-enriched Embryo Transfer Medium for Frozen-thawed Embryo Transfer

In Vitro Fertilization Clinical Trial

Official title:

Randomized Controlled Trial Comparing Hyaluronan-enriched Embryo Transfer Medium Versus Control for Frozen-thawed Embryo Transfer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02725827
• Other study ID #: UW 16-158
• Status: Completed
• Phase: N/A
• Start date: April 2016
• Est. completion date: January 2019

Study information

• Verified date: January 2019
• Source: The University of Hong Kong
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized-controlled trial evaluating the effect of the use of hyaluronan (HA)-enriched embryo transfer medium on the live birth rate in women undergoing frozen-thawed embryo transfer. For half of the women, hyaluronan-enriched medium will be used as embryo transfer medium. For the other half of women, a control will be used.

Description:

Women being scheduled for FET will be assessed for eligibility. Eligible women will be recruited for the study and each woman will only be included in the study with one FET cycle. Informed written consent will be obtained. Their baseline characteristics will be collected.

Women with regular ovulatory cycles will undergo the standard procedures of blood taking to identify the day of luteinizing hormone (LH) surge. Women with irregular cycles will either receive clomiphene or letrozole followed by detection of the LH surge, or undergo hormone replacement therapy (HRT) cycle with oral oestradiol 6 mg daily for 14 days for endometrial priming followed by the addition of vaginal micronized progesterone 100 mg three times daily. HRT cycle may also be used for scheduling purposes.

Embryo transfer will be performed 3 or 4 days (for cleavage-stage embryos) or 6 or 7 days (for blastocysts) after the LH surge. For women in HRT cycles, FET will be scheduled on the 4th or 5th day (for cleavage-stage embryos) or the 7th or 8th day (for blastocysts) of starting vaginal progesterone. They will continue oral oestradiol and vaginal progesterone after FET up to 12 weeks of gestation.

Randomization:

One day before scheduled FET, recruited women will be randomized into one of the following two groups: (1) HA group and (2) control group according to a computer-generated randomization list prepared by a designated research nurse.

One the day of FET, frozen embryos or blastocysts will be thawed and incubated for at least 10 minutes in embryo transfer medium. For women allocated to the HA group, EmbryoGlue (Vitrolife) will be used as embryo transfer medium, while in the control group the usual medium used in the study center will used. The main difference between the two media is that EmbryoGlue contains a higher concentration of HA.

The rest of the embryo transfer procedure will be the same as the usual practice.

Blinding:

The patient and the physicians performing the FET and involved in her care will not know the group allocation. Only the embryologist will know the group allocation, but they will not be involved in the patient care, the FET procedure and subsequent assessment.

Follow-up and data collection:

A urine pregnancy test is performed 18 days after the LH surge or starting vaginal progesterone. If the pregnancy test is positive, transvaginal ultrasound will be performed 2 weeks later to locate the pregnancy and fetal viability. Subsequent management will be the same as other women with early pregnancy. They will be referred for antenatal care when the pregnancy is on-going at 8 weeks.

Follow-up:

Written consent regarding retrieval of pregnancy and delivery data from both public and private sectors will be sought from the patient at the time of study. The obstetric outcomes will be traced from the electric patient record system if the patients deliver in Hospital Authority hospitals. A pre-formatted letter with replying address available will be given to the patient at the end of the study period and is to be filled by the private obstetrician and returned to us after delivery. If no reply letter is received 2-3 months after the expected date of confinement of the patient, a letter including patient's authorization will be sent to the corresponding private obstetrician to retrieve the information of the pregnancy outcomes. The outcome of the pregnancy (delivery, miscarriage), number of babies born, birth weights and obstetrics complications will be recorded.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 550
• Est. completion date: January 2019
• Est. primary completion date: January 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 42 Years

Eligibility

Inclusion Criteria:

• Women panning to replacing early cleavage embryos or blastocysts after thawing.

Exclusion Criteria:

• Frozen early cleavage embryos thawed and cultured to blastocysts prior to transfer as requested by the patient

• Preimplantation genetic diagnosis treatment

• Use of donor oocytes or donor embryos

• Endometrial thickness <8mm on the day of the luteinizing hormone surge or after two weeks of estrogen in hormonal replacement cycles

• Hydrosalpinx shown on pelvic scanning and not surgically treated

Related Conditions & MeSH terms

• In Vitro Fertilization
• Infertility
• Subfertility

Intervention

Other:
• EmbryoGlue (Vitrolife)
A hyaluronan-enriched embryo transfer medium
• Control medium
The usual embryo transfer medium used in the study centres.

Locations

Country	Name	City	State
Hong Kong	Kwong Wah Hospital	Hong Kong
Hong Kong	Queen Mary Hospital, University of Hong Kong	Hong Kong

Sponsors (2)

Lead Sponsor	Collaborator
The University of Hong Kong	Kwong Wah Hospital

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Live-birth rate per embryo transfer procedure		1 year
Secondary	pregnancy rate	positive urine pregnancy test	4 weeks
Secondary	clinical pregnancy rate	presence of intrauterine gestational sac on ultrasound	4 weeks
Secondary	implantation rate	number of gestational sacs per embryo transferred	8 weeks
Secondary	on-going pregnancy rate	viable pregnancy beyond gestation 8 weeks	8 weeks
Secondary	adverse events		12 weeks
Secondary	obstetric complications		1 year